股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 萬嘉集團控股有限公司 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00401 | | 說明 | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 560,222,136 | | 0 | | 560,222,136 | | 增加 / 減少 (-) | | | | | | | | | | 本月底結存 | | | | 560,222,136 | | 0 | | 560,222,136 | 第 2 頁 共 10 頁 v 1.1.1 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 ...

Financial Performance - Revenue for the period was approximately HKD 85,706,000, an increase of about 2.40% compared to HKD 83,695,000 in the same period last year[5] - The company reported a loss attributable to owners of approximately HKD 712,000, compared to a profit of HKD 1,256,000 in the previous year[5] - Basic and diluted loss per share was approximately HKD 0.127, compared to a profit of HKD 0.22 per share in the previous year[7] - Gross profit for the period was HKD 25,774,000, down from HKD 26,433,000 in the previous year[6] - The company reported a total comprehensive income of HKD 152,000, significantly lower than HKD 2,791,000 in the previous year[6] - Total comprehensive income for the period ended September 30, 2025, was HKD 289,000, a significant decrease from HKD 2,726,000 in the previous period[17] - The group recorded a loss attributable to the owners of approximately HKD 712,000, compared to a profit of HKD 1,256,000 in the previous year[61] Cash Flow and Liquidity - Total cash and cash equivalents as of September 30, 2025, were approximately HKD 18,918,000, down from HKD 24,083,000 as of March 31, 2025[5] - As of September 30, 2025, the net cash generated from operating activities was HKD 3,126,000, compared to HKD 11,159,000 for the same period in 2024, representing a decrease of approximately 72%[17] - The net cash used in financing activities was HKD 8,444,000 for the six months ended September 30, 2025, compared to a net cash inflow of HKD 1,630,000 in 2024[17] - The cash and cash equivalents decreased by HKD 5,317,000 during the six months ended September 30, 2025, compared to an increase of HKD 12,815,000 in the same period of 2024[17] Assets and Liabilities - Total assets amounted to HKD 108,159,000 as of September 30, 2025, compared to HKD 106,822,000 as of March 31, 2025[8] - Current liabilities increased to HKD 30,599,000 from HKD 29,002,000 in the previous period[9] - Non-current assets decreased to HKD 48,082,000 from HKD 50,208,000[8] - Total liabilities as of September 30, 2025, were HKD 39,374,000, with HKD 33,404,000 classified liabilities and HKD 5,970,000 unallocated corporate liabilities[30] Revenue Breakdown - Revenue from external customers for the six months ended September 30, 2025, was HKD 85,706,000, with HKD 25,617,000 from pharmaceutical wholesale and distribution, and HKD 60,089,000 from hemodialysis treatment and consulting services[27] - Revenue from the wholesale business was approximately HKD 25,617,000, a decrease of about 5.93% from HKD 27,232,000 in the previous year, attributed to reduced demand from hospitals and clinics[48][53] - Revenue from the dialysis business was approximately HKD 60,089,000, an increase of about 6.42% from HKD 56,463,000 in the previous year, driven by an increase in the number of patients treated[49][54] Shareholder Information - As of September 30, 2025, Mr. Wang holds a total equity interest of 30.12% in the company, including 156,862,198 shares and 2,500,000 options[77] - Major shareholder 威揚 holds 156,862,198 shares, representing approximately 28.00% of the total issued shares as of September 30, 2025[79] - 泓港財務有限公司, Expert Wealth Investments Limited, and 吳國輝 have released their security interest in the 156,862,198 shares held by 威揚[80] Stock Options and Share Schemes - A total of 80,793,054 stock options have been granted under the 2013 stock option plan, representing approximately 14.42% of the total issued shares[83] - The 2023 stock option plan allows for the issuance of 56,022,213 stock options, which is about 10.00% of the total issued shares[84] - The exercise price for stock options ranges from 0.094 to 0.668 per share, with various exercise periods extending to 2033[83] - The 2023 Share Option Scheme was adopted on September 15, 2023, to attract and retain top talent and provide additional incentives to eligible participants[88] Corporate Governance - The audit committee, consisting of three independent non-executive directors, has reviewed the group's unaudited consolidated results for the period and confirmed compliance with applicable accounting standards[101] - The Compensation Committee was established on September 24, 2013, and includes one executive director and three independent non-executive directors[102] - The main responsibilities of the Nomination and Corporate Governance Committee include reviewing the board's structure and recommending changes, as well as maintaining effective corporate governance and internal control systems[104] Compliance and Risk Management - The company is actively monitoring compliance with external regulatory requirements and assessing their impact on existing operations[67] - Following a recent compliance issue, the company is implementing corrective measures to ensure adherence to applicable laws and regulations[74] - The company has not engaged in any major acquisitions or disposals during the reporting period[71] Employee Information - As of September 30, 2025, the company employed 177 full-time employees, with total employee costs amounting to approximately HKD 14,424,000, an increase from HKD 13,360,000 in 2024[73]

WANJIA GROUP HOLDINGS LIMITED 萬嘉集團控股有限公司 ( 於開曼群島註冊成立的有限公司 ) (股份代號：401) 2025 年 11 月 26 日 致本公司的非登記股東 於本公司網站刊發公司通訊的通知 本公司謹通知 閣下，萬嘉集團控股有限公司 (「本公司」) 之下述公司通訊(「公司通訊」) 的英文本及中文 本，現已登載於本公司網站 www.wanjia-gp.com: • 中期報告2025/2026 請於本公司網站內的「投資者關係」以閱覽公司通訊。公司通訊亦已載於「披露易」網站 www.hkexnews.hk 。 致： 萬嘉集團控股有限公司 （「公司」）（股份代號：401） 卓佳證券登記有限公司轉交 香港夏慤道 16 號 遠東金融中心 17 樓 提示 作為非登記股東，如有意以電子方式收取公司通訊1的發佈通知 ， 閣下應聯絡 閣下持有股份的銀行、經紀、託管商、代理人或香 港中央結算（代理人）有限公司（統稱「中介公司」），並向 閣下的中介公司提供 閣下的電子郵件地址。 倘 閣下擬收取公司通訊的印刷本，可填妥隨附之申請表格及利用郵寄標籤寄回本公司之香港股份過戶登記分 處 – 卓佳證券登記 ...

承董事會命 萬嘉集團控股有限公司 行政總裁及執行董事 王佳駿 WANJIA GROUP HOLDINGS LIMITED 萬嘉集團控股有限公司 ( 於開曼群島註冊成立的有限公司 ) (股份代號：401) 各位註冊股東： 於本公司網站刊登公司通訊之通知 謹此通知 閣下，萬嘉集團控股有限公司（「本公司」）之下述公司通訊（「本次公司通訊」）之英文及中文版本， 現已於本公司網站 www.wanjia-gp.com 及香港聯合交易所有限公司（「聯交所」）網站 www.hkexnews.hk 登載；或 本次公司通訊之印刷本已按 閣下所選擇之語言版本隨件附上（如適用）： • 中期報告2025/2026 請於本公司網站內的「投資者關係」以閱覽公司通訊。公司通訊亦已載於「披露易」網站www.hkexnews.hk。 倘 閣下因任何原因於瀏覽本公司網站登載的本次公司通訊時出現任何困難，本公司在接獲 閣下要求時，將立 即免費發送所選定的語言版本的本次公司通訊的印刷本予 閣下。請於附奉之變更申請表格（「變更申請表格」） （變更申請表格下方附有已預付郵費的郵寄標籤）甲部適當空格內劃上「✓」號。倘 閣下欲更改本公司所有日後 公司通訊（「 ...

Core Viewpoint - Wan Jia Group (00401) reported a loss attributable to shareholders of HKD 712,000 for the six months ending September 30, 2025, despite a revenue increase of 2.4% to HKD 85.706 million, driven by growth in the blood dialysis business [1] Financial Performance - Revenue for the period was HKD 85.706 million, reflecting a year-on-year increase of 2.4% [1] - The company recorded a loss attributable to shareholders of HKD 712,000, compared to a profit of HKD 1.256 million in the same period last year [1] - Basic loss per share was HKD 0.127 [1] Business Segment Analysis - The increase in revenue was primarily driven by the growth in the blood dialysis business [1]

Core Points - The company reported a revenue of HKD 85.706 million for the six months ending September 30, 2025, representing a year-on-year increase of 2.4% [1] - The company recorded a loss attributable to shareholders of HKD 0.712 million, compared to a profit of HKD 1.256 million in the same period last year [1] - The basic loss per share was HKD 0.127 [1] - The increase in revenue was driven by the growth in the blood dialysis business [1]

Group 1 - The core point of the article is that Wan Jia Group (00401.HK) reported a revenue of approximately HKD 85.706 million for the six months ending September 30, 2025, representing an increase of about 2.40% compared to the same period in 2024, primarily due to increased revenue from its dialysis business [1] - The company reported a loss attributable to shareholders of approximately HKD 712,000 for the period, compared to a profit of approximately HKD 1.256 million in 2024 [1] - The basic and diluted loss per share for the period was approximately HKD 0.127 [1]

Financial Performance - The revenue for the six months ended September 30, 2025, was approximately HKD 85,706,000, an increase of about 2.40% compared to HKD 83,695,000 for the same period in 2024, driven by growth in the hemodialysis business[3] - The company reported a loss attributable to owners of approximately HKD 712,000 for the current period, compared to a profit of approximately HKD 1,256,000 in the same period last year[3] - Gross profit for the current period was approximately HKD 25,774,000, a decrease from HKD 26,433,000 in the prior year[4] - The company recorded a total comprehensive income of HKD 152,000 for the current period, a significant decrease from HKD 2,791,000 in the same period last year[4] - The operating profit for the period was HKD 795,000, while the loss for the period amounted to HKD 849,000, indicating a decline compared to the previous year's profit of HKD 1,322,000[27][29] - The group reported a loss attributable to owners of approximately HKD 712,000, compared to a profit of HKD 1,256,000 in the previous year[62] Cash and Liquidity - Total cash and cash equivalents as of September 30, 2025, were approximately HKD 18,918,000, down from HKD 24,083,000 as of March 31, 2025[3] - The net cash generated from operating activities was HKD 3,126,000, a significant decrease from HKD 11,159,000 in the previous year[16] - The financing activities resulted in a net cash outflow of HKD 8,444,000, contrasting with a net inflow of HKD 1,630,000 in the prior period[16] - As of September 30, 2025, cash and cash equivalents decreased to HKD 18,918,000 from HKD 32,062,000 at the end of the previous period[16] Revenue Segmentation - For the six months ended September 30, 2025, the total revenue from external customers was HKD 85,706,000, with HKD 25,617,000 from pharmaceutical wholesale and distribution, and HKD 60,089,000 from dialysis treatment and consulting services[27] - The financial performance in the pharmaceutical wholesale and distribution segment showed a revenue decrease from HKD 27,232,000 in the previous year to HKD 25,617,000[29] - The dialysis treatment and consulting services segment reported a revenue increase from HKD 56,463,000 to HKD 60,089,000, reflecting growth in this area[29] Assets and Liabilities - The total assets of the group as of September 30, 2025, were approximately HKD 108,159,000, compared to HKD 106,822,000 as of March 31, 2025[7] - Current liabilities increased to approximately HKD 30,599,000 from HKD 29,002,000 as of March 31, 2025[8] - The company’s total equity attributable to owners was approximately HKD 67,171,000 as of September 30, 2025, compared to HKD 66,882,000 as of March 31, 2025[7] - Trade receivables increased to HKD 32,252 million as of September 30, 2025, up from HKD 25,074 million as of March 31, 2025[39] - Trade payables increased significantly to HKD 16,525 million as of September 30, 2025, from HKD 6,896 million as of March 31, 2025[42] Employee and Operational Costs - The group’s employee costs, including directors' remuneration, rose to HKD 14,424 million for the six months ended September 30, 2025, compared to HKD 13,360 million in the previous year[32] - Selling and distribution expenses for the period were approximately HKD 15,793,000, an increase of about 4.76% from HKD 15,075,000 in the previous year[58] - Administrative expenses for the period were approximately HKD 9,186,000, an increase of about 1.44% from HKD 9,056,000 in the previous year, primarily due to increased salary expenses[59] Dividend and Shareholder Information - The board of directors did not recommend the payment of an interim dividend for the current period, consistent with the previous year[3] - The company has not held any distributable reserves for shareholders during the reporting period, as per applicable laws in the Cayman Islands[15] - The group has not proposed any interim dividend for the period, consistent with the previous year[45] Stock Options and Equity - A total of 80,793,054 stock options have been granted under the 2013 stock option plan, with 14.42% of the company's issued shares represented by unexercised options[85] - The 2023 stock option plan allows for the issuance of 56,022,213 stock options, which accounts for approximately 10.00% of the total issued shares[86] - The company has granted 44,800,000 stock options to employees under the 2023 plan, representing 7.99% of the total issued shares[85] - The total number of stock options granted to directors amounts to 9,733,832, which is 1.74% of the total issued shares[85] Compliance and Regulatory Matters - The company announced a temporary suspension of the service agreement with Wuhua Medical Insurance Management Center for 61 days starting November 1, 2025, due to non-compliance issues[77] - The company is implementing corrective measures to comply with the notice from Wuhua Medical Insurance Management Center, including a comprehensive internal control review of the hemodialysis center's operations[76] - The company has verified that no similar non-compliance issues were found in other hemodialysis centers operated by the group[76] Corporate Governance - The audit committee, established in September 2013, includes three independent non-executive directors and is responsible for overseeing financial reporting and internal controls[103] - The remuneration committee, also established in September 2013, determines the specific remuneration of executive directors and reviews stock option grants based on performance without additional performance targets[105]

Core Viewpoint - Wan Jia Group (00401.HK) announced a board meeting scheduled for November 19, 2025, to discuss various matters including the unaudited interim results for the six months ending September 30, 2025 [1] Group 1 - The board will consider and approve the company's and its subsidiaries' unaudited interim results [1] - The board will discuss the potential declaration of an interim dividend, if applicable [1] - The board may consider suspending the transfer of company shares, if necessary [1] - The meeting will address any other matters that may arise [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈 全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 WANJIA GROUP HOLDINGS LIMITED 萬嘉集團控股有限公 司 於本公佈日期，董事會由一名執行董事王佳駿先生、一名非執行董事肖致信 醫生以及三名獨立非執行董事劉勇平博士、陳詠珊女士及許微女士組成。 1. 考慮及通過本公司及其附屬公司截至二零二五年九月三十日止六個月之 未經審核業績（「中期業績」），以及通過將於香港聯合交易所有限公司網 站及本公司之網站刊登有關中期業績之公佈； 2. 考慮派付中期股息（如有）； 3. 考慮暫停辦理本公司股份過戶登記手續（倘有需要）；及 4. 處理任何其他事項。 王佳駿 香港，二零二五年十一月三日 （於開曼群島註冊成立之有限公司） （股份代號：401) 董事會會議通知 萬嘉集團控股有限公司（「本公司」）之董事會（「董事會」）謹此宣佈，董事會將 於二零二五年十一月十九日（星期三）於香港九龍廣東道25號海港城港威大廈1 期18樓01室舉行會議，以商議下列事項： ...